Specialist medical terminology

Autoimmune disease

Disease, in which the immune system attacks it's own body.

Antibody

Protein substance that targets one specific substance in the body and renders it harmless.

Biologic agent

Drug produced using biotechnology methods.

Glucocorticosteroids

Anti-inflammatory hormones that are produced in the adrenal cortex or that can be manufactured as synthetic substances, e.g. cortisone.

IL-17

Abkürzung für den Botenstoff Interleukin-17. Dieser wird von im Eiter vorkommenden Fresszellen und T Zellen produziert und wird stark entzündlich, er ist ein wichtiger Botenstoff ind er Psoriasis.

Immunosuppressant

Medication, which suppresses or reduces the body's own defense by the immune system.

Keratinocytes

Horn cells of the outermost layer of the skin.

Physical therapy

Treatment type based on physical methods.

Plaque psoriasis

Most common form of psoriasis with development of plaques.

Psoriatic arthritis (PsA)

Chronic inflammatory disease of the joints of psoriasis patients that is due to dysfunction in the immune system.

Subcutaneous injection

Pharmaceutical form, in which the medication is injected under the skin.

T-cell modulator

Biologic agent, which binds to T-cells, i.e. cells from the body's own immune system, and thus reduces the formation of pro-inflammatory neurotransmitters.

TNF-α (alpha) blocker

Biologic, which binds to the neurotransmitter TNF-α, in order to inhibit its inflammatory effect.

Trigger

The emergence of a disease triggering factor.

Anti-IL-12/23 therapy

Fully human antibody therapy which is used to neutralise the inflammatory neurotransmitters interleukin 12 and interleukin 23.

Anti-IL-17 Therapie

Rein menschliche Antikörper-Therapie, mit der die Entzündungs-Botenstoffe Interleukin-17 neutralisiert werden.

Balneo-phototherapie

Combined application of bathing and light therapy.

Neurotransmitter

Substance produced in the body, which serves to chemically transmit signals between the body's cells.

IL-12/23

Abbreviation for the neurotransmitters interleukin 12 and interleukin 23, which are attributed a central role in the development of psoriasis.

Immune system

Body's own defense system.

PASI (Psoriasis Area and Severity Index)

Measurement tool that determines the severity of the psoriasis and also scores the efficacy of a medication in clinical studies. For the assessment of severity, the strength of the redness, scaling, thickening of the skin and the extent of the psoriasis across the surface of the body on arms, legs, head and torso are included.

Plaque

Reddish skin area appearing scaly, typical visible symptom for psoriasis disease.

Psoralen

Medicinal substance that increases the skin's photosensitivity.

PUVA

Combined treatment with psoralen and UV-A irradiation.

Systemic treatment

Internal treatment, where the medication is delivered into the body by tablets, injections or infusions.

TNF-α (Alpha)

Tumour necrosis factor α, an anti-inflammatory neurotransmitter of the immune system

Topical therapy

External application in which the medication is applied directly onto the affected area.